WO2010022193A3 - Extrusion à chaud de multiparticules à libération modifiée - Google Patents

Extrusion à chaud de multiparticules à libération modifiée Download PDF

Info

Publication number
WO2010022193A3
WO2010022193A3 PCT/US2009/054374 US2009054374W WO2010022193A3 WO 2010022193 A3 WO2010022193 A3 WO 2010022193A3 US 2009054374 W US2009054374 W US 2009054374W WO 2010022193 A3 WO2010022193 A3 WO 2010022193A3
Authority
WO
WIPO (PCT)
Prior art keywords
particulates
modified release
release multi
hot
melt extrusion
Prior art date
Application number
PCT/US2009/054374
Other languages
English (en)
Other versions
WO2010022193A2 (fr
Inventor
James W. Mcginity
Sandra Schilling
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Priority to BRPI0917358A priority Critical patent/BRPI0917358A2/pt
Priority to EP09808796.8A priority patent/EP2334287A4/fr
Priority to CA2734646A priority patent/CA2734646C/fr
Priority to MX2011001864A priority patent/MX2011001864A/es
Priority to JP2011523974A priority patent/JP2012501967A/ja
Priority to RU2011110100/15A priority patent/RU2483713C2/ru
Priority to CN2009801413687A priority patent/CN102271661A/zh
Publication of WO2010022193A2 publication Critical patent/WO2010022193A2/fr
Publication of WO2010022193A3 publication Critical patent/WO2010022193A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/05—Filamentary, e.g. strands
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
    • B29K2105/0035—Medical or pharmaceutical agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mechanical Engineering (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur des compositions et des procédés d’élaboration d’une formulation pharmaceutique à libération modifiée et sur un procédé de préparation permettant d’incorporer des multiparticules à libération modifiée dans une matrice polymère ou de type cire. Lesdites multiparticules à libération modifiée comprennent une quantité efficace d’un composé thérapeutique présentant un profil de libération de médicament connu ou souhaité. Les multiparticules à libération modifiée peuvent inclure un enrobage polymère ou peuvent être incorporées dans une particule ou dans un matériau de noyau. La matrice polymère comprend un polymère thermoplastique ou un vecteur lipophile ou un mélange de ceux-ci, qui se ramollit ou fond à température élevée et permet la distribution des multiparticules à libération modifiée dans la matrice polymère durant le traitement thermique. Des composés de formulation et des conditions de traitement sont sélectionnés de manière à préserver les caractéristiques de libération contrôlée et/ou les propriétés de protection médicamenteuse des multiparticules à libération modifiée originales.
PCT/US2009/054374 2008-08-20 2009-08-20 Extrusion à chaud de multiparticules à libération modifiée WO2010022193A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BRPI0917358A BRPI0917358A2 (pt) 2008-08-20 2009-08-20 formulação farmacêutica de liberação controlada e método.
EP09808796.8A EP2334287A4 (fr) 2008-08-20 2009-08-20 Extrusion à chaud de multiparticules à libération modifiée
CA2734646A CA2734646C (fr) 2008-08-20 2009-08-20 Extrusion a chaud de multiparticules a liberation modifiee
MX2011001864A MX2011001864A (es) 2008-08-20 2009-08-20 Extrusion de fusion en caliente de multiples particulas de liberacion modificada.
JP2011523974A JP2012501967A (ja) 2008-08-20 2009-08-20 調節放出型多粒子のホットメルト押出成形
RU2011110100/15A RU2483713C2 (ru) 2008-08-20 2009-08-20 Экструзия горячего расплава множественных частиц модифицированного высвобождения
CN2009801413687A CN102271661A (zh) 2008-08-20 2009-08-20 缓释多颗粒的热熔挤出

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9043908P 2008-08-20 2008-08-20
US61/090,439 2008-08-20
US10702708P 2008-10-21 2008-10-21
US61/107,027 2008-10-21

Publications (2)

Publication Number Publication Date
WO2010022193A2 WO2010022193A2 (fr) 2010-02-25
WO2010022193A3 true WO2010022193A3 (fr) 2010-05-27

Family

ID=41696597

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/054374 WO2010022193A2 (fr) 2008-08-20 2009-08-20 Extrusion à chaud de multiparticules à libération modifiée

Country Status (9)

Country Link
US (2) US9192578B2 (fr)
EP (1) EP2334287A4 (fr)
JP (2) JP2012501967A (fr)
CN (1) CN102271661A (fr)
BR (1) BRPI0917358A2 (fr)
CA (1) CA2734646C (fr)
MX (1) MX2011001864A (fr)
RU (1) RU2483713C2 (fr)
WO (1) WO2010022193A2 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US9061027B2 (en) 2004-08-27 2015-06-23 Board Of Regents, The University Of Texas System Enhanced delivery of drug compositions to treat life threatening infections
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8383152B2 (en) 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
HUE030803T2 (en) 2008-05-09 2017-06-28 Gruenenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form using a spraying step \ t
RU2483713C2 (ru) 2008-08-20 2013-06-10 Борд Оф Риджентс, Зе Юниверсити Оф Техас Систем Экструзия горячего расплава множественных частиц модифицированного высвобождения
AR077420A1 (es) 2009-07-22 2011-08-24 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion para opiaceos sensibles a la oxidacion
EP2456427B1 (fr) 2009-07-22 2015-03-04 Grünenthal GmbH Formule de dosage pharmaceutique extrudée thermofusible à libération prolongée
ES2486791T3 (es) 2010-09-02 2014-08-19 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende una sal inorgánica
JP5933553B2 (ja) 2010-09-02 2016-06-15 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング アニオン性ポリマーを含む不正使用抵抗性剤形
DE102011015370A1 (de) * 2011-03-29 2012-10-04 Emodys Gmbh Matrix für eine orale Darreichungsform, Verfahren zu deren Herstellung sowie Verwendung derselben
RS56527B1 (sr) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
LT2736495T (lt) 2011-07-29 2017-11-10 Grünenthal GmbH Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu
US9884042B2 (en) 2011-09-14 2018-02-06 Celgene Corporation Formulations of cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide
CA2864949A1 (fr) 2012-02-28 2013-09-06 Grunenthal Gmbh Forme pharmaceutique inviolable comprenant un compose pharmacologiquement actif et un polymere anionique
EP2838512B1 (fr) 2012-04-18 2018-08-22 Grünenthal GmbH Forme pharmaceutique inviolable et résistante au basculement de dose
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
WO2014139803A1 (fr) * 2013-03-15 2014-09-18 AbbVie Deutschland GmbH & Co. KG Procédé et appareil de mesure d'une formulation plastifiée
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
GB201312245D0 (en) * 2013-07-08 2013-08-21 Gorman Eddie O An extrusion process
MX368846B (es) 2013-07-12 2019-10-18 Gruenenthal Gmbh Forma de dosificación resistente a la alteración que contiene polímero de acetato de etilen-vinilo.
WO2015071394A1 (fr) * 2013-11-15 2015-05-21 Dsm Ip Assets B.V. Formulation de composés modérément solubles obtenue par extrusion à chaud
EP3073994A1 (fr) 2013-11-26 2016-10-05 Grünenthal GmbH Préparation de composition pharmaceutique en poudre par cryo-broyage
US10406234B2 (en) 2014-03-24 2019-09-10 Kashiv Biosciences, Llc Method of manufacturing fine particles suitable for orally disintegrating pharmaceutical dosage forms
EP3142646A1 (fr) 2014-05-12 2017-03-22 Grünenthal GmbH Formulation pour capsule à libération immédiate résistant aux manipulations illicites comprenant du tapentadol
AU2015266117A1 (en) 2014-05-26 2016-11-24 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
CA2964068A1 (fr) * 2014-09-19 2016-03-24 Board Of Regents, The University Of Texas System Procedes de preparation d'extrudats
EA035434B1 (ru) 2015-04-24 2020-06-15 Грюненталь Гмбх Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
US20170296476A1 (en) 2016-04-15 2017-10-19 Grünenthal GmbH Modified release abuse deterrent dosage forms
CN109640947A (zh) 2016-08-05 2019-04-16 株式会社新日本科学 鼻内药物粉末组合物
CN106176682A (zh) * 2016-08-30 2016-12-07 铜陵翔宇商贸有限公司 茶碱缓释制胶囊剂及其制备方法
PL3449931T3 (pl) * 2017-08-28 2020-06-01 Ever Neuro Pharma Gmbh Zastosowanie cerebrolizyny
ES2938608T3 (es) * 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
CN111465390A (zh) 2017-10-13 2020-07-28 格吕伦塔尔有限公司 调释防滥用剂型
EP3728543A1 (fr) 2017-12-21 2020-10-28 Danisco US Inc. Granulés thermofusibles contenant des enzymes, comprenant un déshydratant thermotolérant
CN108619523B (zh) * 2018-03-23 2020-06-30 浙江工业大学 一种可用于快速热塑包衣制剂的包衣膜片及其制备方法
WO2019209290A1 (fr) * 2018-04-25 2019-10-31 Hewlett-Packard Development Company, L.P. Libération sélective de matériau dans une capsule thermiquement dégradable
US11931441B2 (en) * 2018-10-10 2024-03-19 The Procter & Gamble Company Personal care product customized by discrete particles and method of apply thereof
CN109674656A (zh) * 2019-01-15 2019-04-26 苏州璞佩珊科技有限公司 一种制备药物制剂的方法
JP7287032B2 (ja) 2019-03-20 2023-06-06 株式会社リコー シート、シート積層体、医薬品、シートの製造方法、及びシート積層体の製造方法
US20210129406A1 (en) * 2019-11-04 2021-05-06 Board Of Regents, The University Of Texas System Drug solvates in thermal processes to make solid dispersions at lower processing temperatures
CN113080436B (zh) * 2021-04-08 2024-03-01 南京纽邦生物科技有限公司 γ-氨基丁酸干混悬剂及其制备方法
CA3224528A1 (fr) * 2021-06-23 2022-12-29 Bionaut Labs Ltd. Formulations d'ingredients pharmaceutiques actifs (api) pour une administration locale par l'intermediaire d'un microrobot actif

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6488963B1 (en) * 1996-06-26 2002-12-03 The University Of Texas System Hot-melt extrudable pharmaceutical formulation
US20040234602A1 (en) * 2001-09-21 2004-11-25 Gina Fischer Polymer release system
US20070298103A1 (en) * 2004-02-12 2007-12-27 Euro-Celtique S.A. Particulates

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194389C (nl) * 1984-06-14 2002-03-04 Novartis Ag Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager.
DE4138513A1 (de) * 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6190591B1 (en) 1996-10-28 2001-02-20 General Mills, Inc. Embedding and encapsulation of controlled release particles
DE19710009A1 (de) 1997-03-12 1998-09-24 Knoll Ag Mehrphasige wirkstoffhaltige Zubereitungsformen
US5958873A (en) * 1997-06-09 1999-09-28 University Of Cincinnati Oral formulation for treatment of bacteria-induced diseases of the colon
ATE251449T1 (de) 1999-06-14 2003-10-15 Cosmo Spa Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
US6936275B2 (en) * 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
RU2213557C2 (ru) * 2001-12-26 2003-10-10 Закрытое акционерное общество "Аксис" Фармацевтическая композиция, обладающая тромболитическими, противовоспалительными и цитопротективными свойствами
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
MXPA04009713A (es) * 2002-04-05 2005-01-11 Euro Celtique Sa Preparacion farmaceutica que contiene oxicodona y naloxona.
DE102004007713A1 (de) 2004-02-16 2005-09-01 Leistritz Extrusionstechnik Gmbh Vorrichtung zur Herstellung gerundeter Pellets
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
US20050287184A1 (en) * 2004-06-29 2005-12-29 Hossainy Syed F A Drug-delivery stent formulations for restenosis and vulnerable plaque
WO2007001451A2 (fr) * 2004-11-09 2007-01-04 Board Of Regents, The University Of Texas System Composition de petites particules medicamenteuses chauffee et stabilisee
CN1795843A (zh) * 2004-12-24 2006-07-05 方君平 零级释放的药物控释系统
US7771632B2 (en) * 2006-05-15 2010-08-10 American Leistritz Extruder Corp. Continuous melt spheronization apparatus and process for the production of pharmaceutical pellets
DE102006035549A1 (de) * 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht
DE102007009242A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
KR101635233B1 (ko) 2008-06-13 2016-06-30 쓰리엠 이노베이티브 프로퍼티즈 컴파니 경량 벽 보수 컴파운드
RU2483713C2 (ru) 2008-08-20 2013-06-10 Борд Оф Риджентс, Зе Юниверсити Оф Техас Систем Экструзия горячего расплава множественных частиц модифицированного высвобождения

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6488963B1 (en) * 1996-06-26 2002-12-03 The University Of Texas System Hot-melt extrudable pharmaceutical formulation
US20040234602A1 (en) * 2001-09-21 2004-11-25 Gina Fischer Polymer release system
US20070298103A1 (en) * 2004-02-12 2007-12-27 Euro-Celtique S.A. Particulates

Also Published As

Publication number Publication date
US20100047340A1 (en) 2010-02-25
JP2014196315A (ja) 2014-10-16
CA2734646C (fr) 2016-06-28
US9827202B2 (en) 2017-11-28
BRPI0917358A2 (pt) 2015-11-17
CN102271661A (zh) 2011-12-07
RU2011110100A (ru) 2012-09-27
WO2010022193A2 (fr) 2010-02-25
CA2734646A1 (fr) 2010-02-25
EP2334287A4 (fr) 2013-12-25
EP2334287A2 (fr) 2011-06-22
MX2011001864A (es) 2011-06-20
RU2483713C2 (ru) 2013-06-10
JP2012501967A (ja) 2012-01-26
US20160101057A1 (en) 2016-04-14
US9192578B2 (en) 2015-11-24

Similar Documents

Publication Publication Date Title
WO2010022193A3 (fr) Extrusion à chaud de multiparticules à libération modifiée
DE602005027477D1 (de) Arzneimittelabgabe aus embolischen mitteln
BRPI0809326B8 (pt) métodos de preparação de microesfera de liberação controlada contendo exendina com camada de revestimento, composição e microesfera
DE60325461D1 (de) Pharmazeutische granulatzusammensetzungen mit sofortiger freisetzung und kontinuierliches verfahren zu ihrer herstellung
WO2006127690A3 (fr) Systemes de distribution permettant de gerer la liberation d'agents sensoriels dans une composition comestible
WO2006032026A3 (fr) Formulations cristallines injectables a action prolongee de metabolites d'estradiol et leurs procedes d'utilisation
ATE405611T1 (de) Verfahren zur herstellung von partikeln aus thermoplastischen polymeren und daraus gewonnenes pulver
WO2006023860A3 (fr) Composition thermoconductrice et son procede de preparation
WO2007041234A8 (fr) Compositions agrochimiques granulaires a liberation progressive et leur procede de preparation
BR9910481A (pt) Composição farmacêutica para comprimido de liberação não-contìnua
CA2660823C (fr) Composition de matiere et procede pour sa fabrication
WO2011077451A3 (fr) Composition pharmaceutique à libération contrôlée
EP2147903A3 (fr) Procédé de répartition de composants granulaires dans des composés de diamant polycristallin
WO2007124303A3 (fr) Articles thermoplastiques et procédés améliorés pour les fabriquer
WO2008013757A3 (fr) Système d'administration et procédé de fabrication de celui-ci
DE602004015907D1 (de) Konjugierte Dienamide, Verfahren zur deren Herstellung, diese enthaltende Zusammensetzungen sowie deren Verwendung
US20070169404A1 (en) Candle made from multiple wax materials with different melting points
EP2368546A4 (fr) Composition pharmaceutique à libération progressive de méthylphénidate
DE602004029569D1 (de) Oberflächlich vernetzte superabsorbierende Partikeln und Verfahren zu ihrer Herstellung
IL210690A (en) Hardening 2-Part Acrylic Compound, Method for Manufacturing Acrylic Polymer, Nerve Cement, Dental, Adhesive, Building Material, and Powder Preparation
AU2017286434B2 (en) Wax melt with filler
WO2010014952A3 (fr) Comprimé à libération prolongée, et leur procédé de fabrication et d'utilisation
WO2008149320A3 (fr) Composition pharmaceutique à libération lente, faite de microparticules
ATE400304T1 (de) Parfümierte zusammensetzung mit kontrollierter freisetzung
DE602007003036D1 (de) Aminoalkoxystyren, Verfahren zu dessen Herstellung, aus diesem gewonnenes Polymer, Verfahren zur Herstellung dieses Polymers und dessen Verwendung

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980141368.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09808796

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2734646

Country of ref document: CA

Ref document number: MX/A/2011/001864

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2011523974

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1949/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2011110100

Country of ref document: RU

Ref document number: 2009808796

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0917358

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110221